Skip to main content
. Author manuscript; available in PMC: 2011 Sep 22.
Published in final edited form as: Cancer Res. 2010 Aug 10;70(17):6804–6814. doi: 10.1158/0008-5472.CAN-10-0409

Figure 4. PIK3CA mutation causes mutant KRAS colorectal tumor HCT116 to grow in vivo in a MEK-independent manner.

Figure 4

A: Mice with established HCT116 KRAS mutant/PIK3CA wild-type (wt PIK3CA, red) and HCT116 KRAS mutant/PIK3CA mutant (mut PIK3CA, blue) xenografts were treated with 5mg/kg of PD0325901 or vehicle only, 5 days/week for the indicated number of days. The results are represented as in Figure 2D.

B and C: Immunoblots of homogenized xenograft tissue after a single 5mg/kg dose of PD0325901. Tumors were excised pretreatment and at indicated times and split in half; (B) one half was flash frozen for immunoblot analysis with indicated antibodies; (C) the other half was formalin fixed, paraffin embedded and used for tissue-section preparation. 8 µm tissue sections were cut and stained with human specific antibody for cleaved PARP.